APTX - アプティニクス (Aptinyx Inc.) アプティニクス

 APTXのチャート


 APTXの企業情報

symbol APTx
会社名 Aptinyx Inc (アプティニクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including depression neuropathic pain migraine traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925 a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc develops AGN-241751 for major depressive disorder indications.   アプティニクスは米国のバイオ医薬品企業。臨床段階で、脳や神経系疾患の治療に対する新規かつ独自の合成小分子の開発・商業化に従事する。同社パイプラインには、糖尿病による末梢神経障害や線維筋痛向けのNYX-2925、外傷後ストレス障害向けのNYX-783、パ―キンソン病認識機能障害向けのNYX-458を含む。本社所在地はイリノイ州エバンストン。   Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
本社所在地 909 Davis Street Suite 600 Evanston IL 60201 USA
代表者氏名 Norbert G. Riedel ノーベルト・G・リーデル
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 847-871-0377
設立年月日 42156
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.aptinyx.com
nasdaq_url https://www.nasdaq.com/symbol/aptx
adr_tso
EBITDA EBITDA(百万ドル) -40.34500
終値(lastsale) 26.41
時価総額(marketcap) 884635275.84
時価総額 時価総額(百万ドル) 917.46160
売上高 売上高(百万ドル) 6.98100
企業価値(EV) 企業価値(EV)(百万ドル) 738.37160
当期純利益 当期純利益(百万ドル) -40.37900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aptinyx Inc revenues increased 78% to $4.6M. Net loss increased 50% to $25M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 53% to $25.5M (expense) General and administrative increase of 43% to $3.2M (expense).

 APTXのテクニカル分析


 APTXのニュース

   Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate  2020/10/27 17:35:10 Benzinga
The market’s skepticism around Aptinyx Inc’s (NASDAQ: APTX ) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiated coverage of Aptinyx with an Overweight rating and a price target of $10. The Aptinyx Thesis: Apart from the PTSD candidate, another two modulators show “meaningful potential,” which could lend upside to the stock over the intermediate- to longer-term, Raymond said. “We understand the skepticism around PTSD but objectively, NYX-783 is the most promising agent in … Full story available on Benzinga.com
   Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option  2020/10/26 20:01:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 16,100,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase additional shares, at a public offering price of $3.00 per share. All of the shares sold in the offering were sold by Aptinyx. The g
   Aptinyx Announces Pricing of Public Offering of Common Stock  2020/10/22 02:59:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the pricing of its public offering of 14,000,000 shares of its common stock at a public offering price of $3.00 per share. All of the shares sold in the offering will be sold by Aptinyx. In addition, Aptinyx has granted the underwriters a 30-day option to purchase up to 2,100,000 addi
   Aptinyx Announces Proposed Public Offering of Common Stock  2020/10/20 20:01:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering. All of the shares sold in the offering will be sold by Aptinyx. Aptinyx also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares t
   Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment  2020/10/20 13:19:39 MarketWatch
Shares of Aptinyx Inc. undefined shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the…
   Aptinyx Reports Second Quarter 2020 Financial Results and Highlights  2020/08/13 20:05:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators. “Despite the continuing COVID-19 health emergency, we have made important progress in advancing our pipeline of clinical-stag
   Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/04 12:37:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT. A live webcast of each presentation will be available on the “Events and Presentations” page in the “Inves
   Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020  2020/07/30 20:01:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-220
   Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020  2020/07/08 12:37:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company’s development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET. The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Disti
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
   Aptinyx Reports Second Quarter 2020 Financial Results and Highlights  2020/08/13 20:05:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators. “Despite the continuing COVID-19 health emergency, we have made important progress in advancing our pipeline of clinical-stag
   Aptinyx to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/04 12:37:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the 2020 Wedbush PacGrow Healthcare Virtual Conference. The presentation will take place on Tuesday, August 11, 2020 at 2:20 PM EDT. A live webcast of each presentation will be available on the “Events and Presentations” page in the “Inves
   Aptinyx to Report Second Quarter Financial Results on Thursday, August 13, 2020  2020/07/30 20:01:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 13, 2020 at 5:00 p.m. ET to report second quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-220
   Aptinyx to Host PTSD-Focused R&D Day on August 5th, 2020  2020/07/08 12:37:00 Business Wire
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it will host a virtual R&D Day focused on the company’s development efforts in post-traumatic stress disorder (PTSD) on Wednesday, August 5, 2020, from 10:00 a.m. to 11:30 a.m. ET. The meeting will feature a presentation from Murray B. Stein MD, MPH, FRCPC. Dr. Stein is Disti
   The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts  2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.

 関連キーワード  (医薬品 米国株 アプティニクス APTX Aptinyx Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)